US Bancorp DE Has $57.79 Million Position in Stryker Corporation $SYK

US Bancorp DE reduced its holdings in shares of Stryker Corporation (NYSE:SYK) by 4.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 164,420 shares of the medical technology company’s stock after selling 8,065 shares during the period. US Bancorp DE’s holdings in Stryker were worth $57,790,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of SYK. Corient Private Wealth LLC grew its holdings in Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after acquiring an additional 1,146,998 shares during the period. Alliancebernstein L.P. grew its holdings in Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after acquiring an additional 741,542 shares during the period. Strive Asset Management LLC acquired a new stake in Stryker during the 3rd quarter worth about $227,389,000. Credit Agricole S A acquired a new stake in Stryker during the 3rd quarter worth about $194,045,000. Finally, Pictet Asset Management Holding SA grew its holdings in Stryker by 190.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 466,256 shares of the medical technology company’s stock worth $163,878,000 after acquiring an additional 305,640 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of recent analyst reports. BTIG Research reiterated a “buy” rating and set a $397.00 price target on shares of Stryker in a report on Tuesday, April 14th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. The Goldman Sachs Group decreased their price target on Stryker from $403.00 to $357.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. UBS Group decreased their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Finally, Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price for the company in a research note on Tuesday, January 6th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $421.11.

Stryker Stock Performance

Shares of SYK opened at $314.64 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The stock has a 50-day moving average of $345.67 and a 200-day moving average of $356.95. The company has a market cap of $120.50 billion, a PE ratio of 37.46, a P/E/G ratio of 1.84 and a beta of 0.92. Stryker Corporation has a one year low of $311.31 and a one year high of $404.87.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts predict that Stryker Corporation will post 14.91 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were paid a $0.88 dividend. The ex-dividend date was Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 41.90%.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Strong cash flow and profitability expansion — Reported net income, operating profit and cash from operations rose materially year-over-year (cash from ops jumped sharply), supporting balance-sheet strength and capital spending. Quiver Quantitative: Q1 results
• Positive Sentiment: Company maintained FY‑2026 EPS guidance (14.900–15.100), signaling management confidence in full‑year recovery despite the soft quarter. Reuters: misses estimates, maintains outlook
• Neutral Sentiment: Company highlighted quick operational recovery from a recent cyber incident; management framed the issue as contained and service delivery resumed. WSJ: cyberattack recovery
• Neutral Sentiment: Ongoing commercial wins and government contract awards provide recurring revenue tailwinds, but these are modest relative to total sales. Quiver: gov’t contracts & institutional activity
• Negative Sentiment: Earnings and revenue missed consensus — Q1 adjusted EPS missed estimates and revenue growth was only ~2.6%, below Street expectations, driving the initial negative market reaction. Zacks: EPS & revenue lag
• Negative Sentiment: Demand weakness in implants and complex-procedure devices weighed on results and led to a contraction in adjusted operating margin (down ~180 bps) and lower adjusted EPS versus prior year. GlobeNewswire: operating results & margin details
• Negative Sentiment: Insider and large institutional selling noted in filings and data feeds, which can add downward pressure on the stock in the near term. Quiver: insider & hedge fund activity

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.